AbbVie’s Skyrizi Machine Is Writing Checks Its Oncology Pipeline Now Has to Cash
Skyrizi hit $4.48B in Q1 2026 revenue. AbbVie is deploying that cash into oncology—and the CLL14 nine-year data just...
Skyrizi
AbbVie’s Post-Humira Safety Net Has a Hole in It — and J&J Just Found It
BNP Paribas flagged J&J's oral psoriasis candidate as a credible Skyrizi rival, and Wall Street mostly shrugged. They shouldn't...